Medicamen Biotech — 360° view

Medicamen Biotech, a company in the Pharmaceuticals industry, reported revenue of ₹55 crore and net profit of ₹4.12 crore for the September 2026 quarter.

Medicamen Biotech (NSE: MEDICAMEQ-BE) closed at ₹285.90 on 20 Nov 2026. Its market capitalisation is ₹402 crore and it trades at 34.7 times earnings.

Share price
₹285.90 (20 Nov 2026)
Market cap
₹402 Cr (20 Nov 2026)
P/E
34.72 (20 Nov 2026)
Revenue
₹55 Cr (September 2026 quarter)
Net profit
₹4 Cr (September 2026 quarter)
ROCE
5.82% (FY26)
ROE
3.95% (FY26)
Book value
₹208 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹319.90 / ₹247.10 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: MEDICAMEQ-BE

Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.